Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
Division of Cardiology, Santo Andre's Hospital, Leiria, Portugal.
J Am Coll Cardiol. 2017 Oct 3;70(14):1760-1776. doi: 10.1016/j.jacc.2017.08.037.
Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.
抗血小板药物为急性缺血综合征（包括冠状动脉和脑血管）的管理以及预防其复发提供一线抗血栓治疗。由于与其他预防策略联合使用时潜在益处和风险的平衡不确定，它们在动脉粥样硬化血栓形成的一级预防中的作用仍存在争议。本共识文件的目的是回顾抗血小板药物的疗效和安全性证据，并为临床心脏病专家提供一个更新的工具，根据合并症和/或介入治疗，指导他们为患有不同临床表现的冠状动脉粥样硬化血栓形成的个体患者选择最合适的抗血小板策略。
